---
title: "LIVE MARKETS-Europe before the bell: Banks are back on the agenda"
description: "European markets are reacting to concerns over the banking sector, particularly U.S. regional banks, with Euro STOXX 50 futures down 1% and S&P 500 futures down 0.7%. In corporate news, BBVA's hostile"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261561509.md"
published_at: "2025-10-17T06:53:06.000Z"
---

# LIVE MARKETS-Europe before the bell: Banks are back on the agenda

> European markets are reacting to concerns over the banking sector, particularly U.S. regional banks, with Euro STOXX 50 futures down 1% and S&P 500 futures down 0.7%. In corporate news, BBVA's hostile takeover bid for Sabadell has failed, leading to a buyback announcement and a 7% rise in shares. Additionally, Novo Nordisk may see a 2% drop after Trump announced price reductions for weight loss drugs. Overall, the market sentiment is cautious ahead of the opening.

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

### EUROPE BEFORE THE BELL BANKS ARE BACK ON THE AGENDA

Worries about the banking sector, or at least U.S. regional banks, that’s what we all want on a Friday morning.

And it’s certainly weighing on stocks with Euro STOXX 50 futures down around 1%, and S&P 500 futures down 0.7% after a 0.6% fall on Thursday. (STXEc1) (ESc1) (.SXP)

It’s hard to know how much we need to worry for now, but U.S. bank stocks fell sharply on Thursday. Click on Morning Bid below for a nice, easy read in.

Then we’ve got the question of what happens to sky-high defence stocks after U.S. President Donald Trump and Russian President Vladimir Putin agreed on Thursday to another summit on the war in Ukraine. The sector has been getting a touch of altitude sickness this week anyway.

Then in terms of company news, we’ve got our own excitement in Europe, as Spain’s BBVA (BBVA.MC) failed to convince Sabadell (SABE.MC) shareholders to back its 16.32-billion euro ($19.07 billion) hostile takeover bid, ending an almost 18-month takeover battle that became one of the country’s most contentious deals in recent years.

BBVA announced a buyback instead, and the shares are liking it on the Tradegate platform, up around 7%.

“If the deal was generally perceived as a good strategic move for BBVA in the long term, but a drag in the short term, given political opposition and delayed synergies during the 3-year no-merger period, it is fair to assume the opposite applies now,” said Jefferies analysts in a note.

Novo Nordisk (NOVOb.CO) is also worth watching after Trump said the price of weight loss drugs will be lowered. Traders expect falls of around 2% at the open.

(Alun John)

### MORNING BID: ADD CREDIT RISK TO A BUBBLE, AND STAND WELL BACK CLICK HERE

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [BBVA.US - Banco Bilbao Vizcaya Argentaria](https://longbridge.com/en/quote/BBVA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 諾和諾德公司首席財務官 Karsten Munk Knudsen 出售了價值超過 830 萬丹麥克朗的股票 | 諾和諾德公司（Novo Nordisk A/S）宣佈，首席財務官卡斯滕·穆克·克努森（Karsten Munk Knudsen）於 2026 年 2 月 10 日以每股 DKK 315.60 的價格出售了 26,246 股，交易總額為 DK | [Link](https://longbridge.com/en/news/275652909.md) |
| 諾和諾德公司將在其愛爾蘭工廠生產 Wegovy | 諾和諾德公司將在愛爾蘭工廠生產 Wegovy | [Link](https://longbridge.com/en/news/275789396.md) |
| Savvy Advisors Inc. 購入了諾和諾德公司 22,138 股股票 $NVO | Savvy Advisors Inc. 在第三季度將其在諾和諾德公司（Novo Nordisk A/S）的持股增加了 83.0%，收購了 22,138 股，使其總持股達到 48,824 股，價值 270 萬美元。其他機構投資者也調整了他們的 | [Link](https://longbridge.com/en/news/275761183.md) |
| 高盛：諾和諾德定價壓力被市場過度定價，口服 Wegovy 將是扭轉信心的關鍵 | 高盛稱，當前股價已完全消化 2026 財年最悲觀預期。市場低估了 Medicare 放開的銷量潛力和口服版 Wegovy 的收入前景。口服 Wegovy 上市表現強勁，已開出 5 萬張處方，其中 9 成為自費需求，顯示剛性市場潛力，將成為扭 | [Link](https://longbridge.com/en/news/275095024.md) |
| 諾和諾德公司計劃開始銷售其減肥重磅藥物 Wegovy 的瓶裝版本 - 彭博社 | 諾和諾德公司計劃開始以小瓶形式銷售其減肥暢銷藥 Wegovy - 彭博新聞 | [Link](https://longbridge.com/en/news/275654518.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.